key: cord-0969098-vrmwk90t
authors: Hogan, C. A.; Stevens, B.; Sahoo, M. K.; Huang, C.; Garamani, N.; Gombar, S.; Yamamoto, F.; Murugesan, K.; Kurzer, J.; Zehnder, J.; Pinsky, B. A.
title: High frequency of SARS-CoV-2 RNAemia and association with severe disease
date: 2020-05-01
journal: nan
DOI: 10.1101/2020.04.26.20080101
sha: d5ad4166689e169c67c4dca08d54dba1ec9a30f6
doc_id: 969098
cord_uid: vrmwk90t

Background: Detection of SARS-CoV-2 RNA in the blood, also known as RNAemia, has been reported, but its prognostic implications are not well understood. This study aimed to determine the frequency of SARS-CoV-2 RNA in plasma and its association with the clinical severity of COVID-19. Methods: An analytical cross-sectional study was performed in a single-center tertiary care institution in northern California and included consecutive inpatients and outpatients with COVID-19 confirmed by detection of SARS-CoV-2 RNA in nasopharyngeal swab specimens. The prevalence of SARS CoV-2 RNAemia and the strength of its association with clinical severity variables were examined and included the need for transfer to an intensive care unit (ICU), mechanical ventilation and 30-day all-cause mortality. Results: Paired nasopharyngeal and plasma samples were included from 85 patients. The overall median age was 55 years, and individuals with RNAemia were older than those with undetectable SARS-CoV-2 RNA in plasma (63 vs 50 years; p=0.001). Comorbidities were frequent including obesity (37.7%), hypertension (30.6%) and diabetes mellitus (22.4%). RNAemia was detected in a total of 28/85 (32.9%) individual patients, including 22/28 (78.6%) who required hospital admission. RNAemia was detected more frequently in individuals who developed severe disease including the need for ICU transfer (32.1% vs 14.0%; p=0.05), mechanical ventilation (21.4% vs 3.5%; p=0.01) and 30-day all-cause mortality (14.3% vs 0%; p=0.01). No association was detected between RNAemia and estimated levels of viral RNA in the nasopharynx. An additional 121 plasma samples from 28 individuals with RNAemia were assessed longitudinally, and RNA was detected for a maximum duration of 10 days. Conclusion: This study demonstrated a high proportion of SARS-CoV-2 RNAemia, and an association between RNAemia and clinical severity suggesting the potential utility of plasma viral testing as a prognostic indicator for COVID-19.

The coronavirus disease 2019 (COVID-19) is most frequently diagnosed from nasopharyngeal 50 (NP) swab samples. Preliminary data suggest that severe acute respiratory syndrome coronavirus 51 2 (SARS-CoV-2) RNA may also be detected in plasma and serum. 1,2 However, the frequency and 52 prognostic implication of viral RNA detection in these sample types is not fully understood. We 53 aim to investigate the association between detectable SARS-CoV-2 RNA in nasopharyngeal swab 54 and plasma samples, and to describe clinical implications of viral RNA detection in plasma. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

A total of 7,240 samples from SHC patients were tested for SARS-CoV-2 corresponding to 4,485 82 outpatients, 2,452 ED patients, and 303 inpatients, and 453 (6.3%) were positive. Of these, 85 83 individuals with paired NP and plasma samples were included for analysis (Table 1 ). The overall was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint (which this version posted May 1, 2020. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint (which this version posted May 1, 2020. was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint (which this version posted May 1, 2020. The dotted background line represents the real-time reverse transcriptase polymerase chain

Antibody response and viraemia during the course of severe 192 acute respiratory syndrome (SARS)-associated coronavirus infection

Detection of severe acute respiratory syndrome 195 coronavirus RNA in plasma during the course of infection

Detection of severe acute respiratory syndrome coronavirus 198 in blood of infected patients

Viral loads in clinical specimens and SARS 200 manifestations